Article thumbnail
Location of Repository

Stem cell transplantation for rheumatic autoimmune diseases

By Thomas Hügle and Jacob M van Laar


Immunoablative therapy and hematopoietic stem cell transplantation (HSCT) is an intensive treatment modality aimed at 'resetting' the dysregulated immune system of a patient with immunoablative therapy and allow outgrowth of a nonautogressive immune system from reinfused hematopoietic stem cells, either from the patient (autologous HSCT) or a healthy donor (allogeneic HSCT). HSCT has been shown to induce profound alterations of the immune system affecting B and T cells, monocytes, and natural killer and dendritic cells, resulting in elimination of autoantibody-producing plasma cells and in induction of regulatory T cells. Most of the available data have been collected through retrospective cohort analyses of autologous HSCT, case series, and translational studies in patients with refractory autoimmune diseases. Long-term and marked improvements of disease activity have been observed, notably in systemic sclerosis, systemic lupus erythematosus, and juvenile idiopathic arthritis, and treatment-related morbidity and mortality have improved due to better patient selection and modifications of transplant regimens. Treatment-related mortality has decreased to approximately 7%. Prospective, randomised, controlled clinical trials are ongoing or planned in systemic sclerosis, systemic lupus erythematosus, and several nonrheumatological conditions

Topics: Review
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1976). A modification of Jerne’s theory of antibody production using the concept of clonal selection.
  2. (2004). A: Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR.
  3. (2002). A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science
  4. (2007). Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect. Biol Blood Marrow Transplant
  5. (2000). Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med
  6. (1991). Arthritis Research & Therapy Vol 10 No 5 Hügle and van Laar Page 8 of 10 (page number not for citation purposes) This article is part of a special collection of reviews, The Scientific Basis of Rheumatology: A Decade of Progress,
  7. (2006). Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler
  8. (2004). Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis
  9. (2008). Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA
  10. (2006). DE: Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum
  11. (2007). DE: High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood
  12. (2002). Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood
  13. (2007). Drobyski WR: Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood
  14. (1996). DW: Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant
  15. (2000). DW: Stem cell transplantation in experimental models of autoimmune disease.
  16. (2001). E: Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp Hematol
  17. (2007). Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science
  18. (2008). Farge D: Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis
  19. (2007). Fibbe WE, Toes RE: Targeting host Bcell immune responses by persistent donor NK-cell alloreactivity following nonmyeloablative allogeneic stem cell transplantation. Blood
  20. (2008). FM: High-dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis
  21. (2008). Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplant
  22. (1997). Gress RE: Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood
  23. (1997). Gress RE: Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood
  24. (2005). Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol
  25. (2008). Hiepe F: Direct assessment of thymic reactivation after autologous stem cell transplantation. Acta Haematol
  26. (2001). High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum
  27. (2003). High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum
  28. (2006). HY: Immunoregulatory effects of allogeneic mixed chimerism induced by nonmyeloablative bone marrow transplantation on chronic inflammatory arthritis and autoimmunity in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum
  29. (2000). Immune ablation and stem-cell therapy in autoimmune disease. Immunological reconstitution after highdose immunosuppression and haematopoietic stem-cell transplantation. Arthritis Res
  30. (2001). Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood
  31. (1998). JC: Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum
  32. (2007). JL: Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells. Blood
  33. (2007). JM: Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum
  34. (1997). KM: Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation.
  35. (2005). Laar JM: Control of systemic B cell-mediated autoimmune disease by nonmyeloablative conditioning and major histocompatibility complex-mismatched allogeneic bone marrow transplantation. Blood
  36. (2006). M: CD4+CD25+ regulatory T cells and graft-versus-host disease. Semin Hematol
  37. (2002). Marmont A: Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant
  38. (1997). marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT).
  39. (2008). Matucci Cerinic M: Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis
  40. (2006). Nobili F: Allogeneic bone marrow transplantation (BMT) for refractory Behçet’s disease with severe CNS involvement. Bone Marrow Transplant
  41. (2006). Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA
  42. (2004). Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus.
  43. (1990). Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells.
  44. (1997). PJ: Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant
  45. (2006). Prakken B: Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood
  46. (2006). Reconstitution of adaptive and innate immunity following allogeneic hematopoietic stem cell transplantation in humans. Cytotherapy
  47. (2008). Ringdén O; Developmental Committee of the European Group for Blood and Marrow Transplantation: Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: a phase II study. Lancet
  48. (1996). RJ: Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood
  49. (2005). RK: Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood
  50. (2008). RK: Autologous non-myeloablative hematopoietic stem cell transplantation for refractory systemic vasculitis. Ann Rheum Dis
  51. (2007). RK: Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant
  52. (2007). RK: Non-myeloablative allogeneic hematopoietic stem cell transplantation for severe systemic sclerosis: graft-versus-autoimmunity without graft-versushost disease? Bone Marrow Transplant
  53. (1998). SD: Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood
  54. (1974). Siegel BV: Transplantation of Autoimmune Potential. I. Development of Antinuclear Antibodies
  55. (2008). SM: Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE
  56. (1993). Taurog JD: Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment.
  57. (2005). Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med
  58. (2005). Tolerance induction by bone marrow transplantation in a multiple sclerosis model. Blood
  59. (2008). Traynor AE: Resolution of SLE-related softtissue calcification following haematopoietic stem cell transplantation. Nephrol Dial Transplant
  60. (2005). Tyndall A; Autoimmune Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT): Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant
  61. (2004). Tyndall A; European Group for Blood and Marrow Transplantation, et al.: Autologous stem cell transplantation for systemic lupus erythematosus. Lupus
  62. (2008). Tyndall A: Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Ann Rheum Dis
  63. (2008). van Wijk F: Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells. Blood
  64. (2004). WG: Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. Arthritis Rheum

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.